Hemp Research — Page 140

Peer-reviewed industrial hemp research papers, sorted by publication date. Browse the latest findings on hemp cultivation, processing, materials science, biomedical applications, and regulatory science from PubMed, OpenAlex, and other indexed sources.

Exploratory survey study on adjunctive use of medical cannabis for Gaucher disease (2024)

Aims : Using an investigator-designed survey tool to confirm that adult patients with type 1 Gaucher disease (GD1) often self-prescribe cannabis products to try to alleviate symptoms such as lingering fatigue, chronic bone and joint pain, loss of energy, anxiety, and depression that persist despite enzyme replacement therapy (ERT) or substrate restriction therapy (SRT). Additionally, to explore whether patient reports of symptom relief and adverse side effects relate to frequency and duration of

Epileptic seizures as an initial symptom for Sturge‑Weber syndrome type III: A report of two cases (2024)

Sturge-Weber syndrome (SWS) type III, a rare neurocutaneous disorder, presents diagnostic challenges due to its variable clinical manifestations. The present study focuses on enhancing the understanding of this syndrome by conducting a detailed analysis of two pediatric cases and providing a comprehensive review of the existing literature. The cases, managed at the Children's Hospital Affiliated to Shandong University (Jinan, China), highlight the diverse clinical presentations and successful ma

An open-label phase I comparator-controlled clinical trial to assess tolerability and pharmacokinetics of IHL-675 A a fixed dose combination of cannabidiol plus hydroxychloroquine in healthy volunteers (2025)

This was a phase I randomised comparator controlled clinical trial that assessed the pharmacokinetics (PK), and tolerability of IHL-675 A, a fixed dose combination (FDC) of cannabidiol (CBD) and hydroxychloroquine sulfate (HCQ), compared to the reference listed drugs Epidiolex (CBD) and Plaquenil (HCQ) in healthy volunteers (HVs). IHL-675 A is Incannex Healthcare Pty Ltd.'s proprietary product formulated using UniGel™ technology consisting of a solid, film coated HCQ tablet contained within a CB

Neurological manifestations in children with congenital Zika (2024)

Case Presentation: AGRB, male, 9 years old, 52kg, previously healthy, born and raised in Pirambu, Bebedouro village, Sergipe.Adtted on 10/09/2022 to the pediatrics sector of the Sergipe Emergency hospital, reporting headache, fever and vomiting for 7 days, with subsequent evolution with pain in the posterior region of the right thigh, in addition to low back pain.Physical examination showed normal breathing and heart rate.Decreased strength in lower limbs, being worse on the left side.No patella

Cannabidiol blood metabolite levels after cannabidiol treatment are associated with broadband EEG changes and improvements in visuomotor and non-verbal cognitive abilities in boys with autism requiring higher levels of support (2024)

Oral cannabidiol (CBD) treatment has been suggested to alleviate severe symptoms of autism spectrum disorder (ASD). While many CBD preparations have been studied in clinical trials involving ASD, none has used purified CBD preparations or preparations approved by the U.S. Food and Drug Administration, nor have they focused on children with ASD with higher support needs. Previous studies have identified several candidate electrophysiological biomarkers of cognitive and behavioral disabilities in

Anticonvulsant Effects of Different Cannabis Extracts in a Zebrafish Model of Epilepsy (2025)

Epilepsy is a widespread neurological disorder that remains a critical global public health challenge. While numerous antiepileptic drugs (AEDs) are available, many patients either fail to achieve adequate seizure control or experience significant side effects. One promising alternative is pure cannabidiol (CBD), but using a whole cannabis extract may be equally effective and preferred for some patients. In the current study, we employed the pentylenetetrazole (PTZ)-induced hyperactivity model i

Drug-resistant epilepsy: modern concepts, integrative mechanisms, and therapeutic advances (2021)

Background: Drug-resistant epilepsy is the cause of severe disability. Multiple questions remain unanswered both in terms of pathogenesis and therapeutic management. For this narrative review, PubMed database and Infomedica library were searched by using “drug-resistance in epilepsy” and “treatment of drug-resistant epilepsy” as key words. The following filters were applied: “Clinical Trial”, “Meta-analysis”, “Multicenter Study”, and “Randomized Controlled Trial”, covering the period of 01.01.20

Sprayable Hybrid Gel with Cannabidiol, Hyaluronic Acid, and Colloidal Silver: A Multifunctional Approach for Skin Lesion Therapy (2025)

<b>Background/Objectives</b>: This study presents the development and characterization of a novel thermoresponsive hydrogel composed of hyaluronic acid (HA), poloxamer 407, cannabidiol (CBD), and colloidal silver (Ag), designed for topical antimicrobial therapy. <b>Methods</b>: The Ag-CBD complex was first synthesized and subsequently incorporated into a HA-poloxamer gel matrix to produce a stable, sprayable formulation with suitable physicochemical properties for dermal applications. <b>Results

Antiepileptic effects of exenatide in penicillin induced acute epilepsy model in rats (2023)

Glucagon-like peptide-1 receptors are widely expressed in the brain and its association with nitric oxide is suggestive ofits role in epilepsy. In this study, we investigated the effects of exenatide, a glucagon-like peptide-1 receptor agonist, on theepileptiform activity induced by penicillin injection. The study used 72 male Wistar albino rats in 9 groups. All groupsexcept the last group which received only exenatide, received intracortical penicillin injection to induce epileptiformactivity.

Medical Cannabis for Patients Over Age 50: A Multi-site, Prospective Study of Patterns of Use and Health Outcomes (2024)

In this cohort of older patients, most of whom suffered from pain-related conditions, medical cannabis seemed to be a safe and effective treatment. Most patients experienced clinically significant improvements in pain, sleep, and quality of life and reductions in co-medication. The cost per QALY was well below the standard for traditional pharmaceuticals, and no SAEs were reported, suggesting that cannabis is a relatively safe and cost-effective therapeutic option for adults dealing with age-rel

PI3K/AKT/mTOR Signalling Inhibitor Chrysophanol Ameliorates Neurobehavioural and Neurochemical Defects in Propionic Acid-induced Experimental Model of Autism (2021)

<title>Abstract</title> Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by social-communication deficits and repetitive behaviour. Several studies have revealed that overactivation of the PI3K/AKT/mTOR signalling pathways during brain development plays an important role in the pathogenesis of autism. The PI3K/AKT/mTOR signalling pathway overexpression produces neurological abnormalities by increasing cell death, neuroinflammation, and oxidative stress. Chrys

Cannabidiol Attenuates Pulmonary Arterial Hypertension by Normalizing the Mitochondrial Function in Vascular Smooth Muscle Cells (2020)

Abstract Pulmonary artery hypertension (PAH) is a chronic disease associated with enhanced proliferation of pulmonary artery smooth muscle cells (PASMCs) and dysfunctional mitochondria, which was with limited therapeutic options. It has been proved that cannabidiol (CBD) had antioxidant effects in many cardiovascular diseases, whereas the efficacy of CBD in PAH is unknown. To defined the effect of CBD in PAH, we explored the functions of CBD in both PASMCs proliferation test in vitro, and preven

Microglial activation is inhibited by selective anti-seizure medications (2025)

ASMs, applied to patients with DRE, have a differential ability to reduce microglial activation and pro-inflammatory microglial morphology in vitro. Moreover, sodium channel blockage modulates inflammation through microglia activation. Taken together these results suggest, that further investigation of patient's immune response to ASMs could be important.

Evaluation of the impact of a clinical pharmacist on a specialty neurology clinic’s adherence to recommended laboratory test monitoring (2021)

<b>BACKGROUND:</b> Pharmacists can have a significant effect on the specialty ambulatory care setting. Specialty medications are potentially high risk and may require frequent laboratory test monitoring to assess for therapy-associated adverse effects. Pharmacists may work under collaborative drug therapy management agreements that allow for the ordering and assessment of recommended laboratory tests in order to optimize safe and effective medication use. The impact of pharmacists on clinic adhe

Effects of the AMPAr antagonist, Perampanel, on Cognitive Function in Rats Exposed to Neonatal Iron Overload (2024)

<title>Abstract</title> Iron accumulation has been associated with the pathogenesis of neurodegenerative diseases and memory decline. As previously described by our research group, iron overload in the neonatal period induces persistent memory deficits, increases oxidative stress, and apoptotic markers. The neuronal insult caused by iron excess generates an energetic imbalance that can alter glutamate concentrations and thus trigger excitotoxicity. Drugs that block glutamatergic receptor, eligib

Analysis of The Effect of Leptin, AMPK, Adiponectin, and NPY Markers on Changes in Body Weight of Childhood Epileptic Using Valproic Acid Monotherapy (2023)

Introduction: Epilepsy is a neurological disorder that occurs due to abnormal neurons in the brain and an imbalance between excitation and inhibition in the central nervous system. The first line of OAE in children is VPA (Valproate Acid). However, long-term use can cause weight gain with a frequency of 10-70%. The underlying mechanism of weight gain in patients remains unclear. Purpose: This study aimed to analyze the relationship between levels of biomarkers AMPK, NPY, Leptin, and Adiponectin

Synthesis and hLDHA Inhibitory Activity of New Stiripentol-Related Compounds of Potential Use in Primary Hyperoxaluria (2024)

Human lactate dehydrogenase A (<i>h</i>LDHA) is a homotetrameric isozyme involved in the conversion of glyoxylate into oxalate in the cytosol of liver cells (hepatocytes) and partially responsible for the overproduction of oxalate in patients with the rare disease called primary hyperoxaluria (PH). Recently, <i>h</i>LDHA inhibition has been validated as a safe therapeutic method to try to control the PH disease. Stiripentol (STP) is an approved drug used in the treatment of seizures associated w

Validating the antiseizure effects of vitexin and related flavone glycosides in zebrafish (2025)

Current epilepsy treatments often fail to provide sufficient control over seizures, highlighting the need for new therapeutic agents. Vitexin, a flavone with antioxidant, anti-inflammatory, and neuroprotective properties, was previously shown to suppress seizure activity in rodent models. Utilizing zebrafish, this study further evaluates the antiseizure properties of vitexin and for the first time, examines the related flavone glycosides: isovitexin, vitexin 2-O-rhamnoside, vitexin-4-O-glucoside